Outbound Relationships |
Type |
Target |
Active |
Characteristic |
Refinability |
Group |
Values |
Salmeterol+fluticasone propionate 25micrograms/125micrograms CFC-free inhaler |
Is a |
Salmeterol+fluticasone propionate |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Salmeterol+fluticasone propionate 25micrograms/125micrograms CFC-free inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Substance with beta-2 adrenergic receptor agonist mechanism of action (substance) |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Salmeterol+fluticasone propionate 25micrograms/125micrograms CFC-free inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Salmeterol (substance) |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Salmeterol+fluticasone propionate 25micrograms/125micrograms CFC-free inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Fluticasone propionate |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Salmeterol+fluticasone propionate 25micrograms/125micrograms CFC-free inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Corticosterone |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Salmeterol+fluticasone propionate 25micrograms/125micrograms CFC-free inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Adrenal hormone agent |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Salmeterol+fluticasone propionate 25micrograms/125micrograms CFC-free inhaler |
Is a |
Fluticasone- and salmeterol-containing product |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Salmeterol+fluticasone propionate 25micrograms/125micrograms CFC-free inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Fluticasone (substance) |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Salmeterol+fluticasone propionate 25micrograms/125micrograms CFC-free inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Fluticasone propionate |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Salmeterol+fluticasone propionate 25micrograms/125micrograms CFC-free inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Corticosterone |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Salmeterol+fluticasone propionate 25micrograms/125micrograms CFC-free inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Adrenal hormone agent |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Salmeterol+fluticasone propionate 25micrograms/125micrograms CFC-free inhaler |
Has manufactured dose form |
forme pharmaceutique inhalatoire |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Salmeterol+fluticasone propionate 25micrograms/125micrograms CFC-free inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Salmeterol xinafoate |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Salmeterol+fluticasone propionate 25micrograms/125micrograms CFC-free inhaler |
Has manufactured dose form |
Inhaler (product) |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|